Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), dominating current treatment of nonmetastatic CRPC and hormone-sensitive prostate cancer (HSPC). The continued uptake of hormonal therapies, plus the expected label expansions of targeted agents (e.g., Janssen / GlaxoSmithKline’s Akeega, Pfizer’s Talzenna, Novartis’ Pluvicto) and anticipated approvals of emerging therapies (e.g., POINT Biopharma’s 177Lu-PNT2002 and Exelixis / Genentech’s Cabometyx + Tecentriq), will drive robust market growth over the 2022-2032 forecast period.


  • What is the estimated size of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates vary by geography, setting, and over time?
  • How will the prostate cancer market evolve over the 10-year forecast period? What are their drivers and constraints?
  • What are the interviewed experts’ insights on the current treatment options for prostate cancer?
  • How will the adoption and anticipated label expansions of biomarker-driven therapies, such as PARP inhibitors and PSMA-targeted radioligands, reshape the prostate cancer treatment landscape?
  • What is the clinical and commercial potential of emerging regimens, like Cabometyx plus Tecentriq and 177Lu-PNT2002? How are they likely to be positioned in the market?


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports